OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment

• The company said the move reduces administrative hurdles by facilitating easier claims processing for hospitals and clinics.
• Yartemlea is the first and only FDA-approved medicine for hematopoietic stem cell transplant-associated thrombotic microangiopathy.
• The company is now eyeing an approval for the treatment by the European Medicines Agency by mid-2026.

Shares of Omeros Corp. (OMER) are on track to close their best week since late December, if gains hold, after the U.S. Centers for Medicare and Medicaid Services assigned a permanent J-code for its recently-approved treatment Yartemlea.

Yartemlea is the first and only approved medicine for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The condition can hit people after a stem cell or bone marrow transplant and is a rare, severe, and potentially fatal complication where microscopic blood clots form in small vessels, damaging organs, particularly the kidneys and brain.

The company said on Thursday that the J-code will become effective on July 1.

What Is The J-Code?

A J-code is an official “billing sticker” that doctors and hospitals use when they give a patient non-orally administered medications, such as injections, infusions, and chemotherapy. A permanent J-code is designed to simplify billing and speed up reimbursement for a treatment when used by patients covered by Medicare, Medicaid and most commercial insurance plans.

Omeros said the move reduces administrative hurdles by facilitating easier claims processing for hospitals and clinics.

“For patients with TA-TMA, access to effective treatment without unnecessary delay is critical,” said CEO Gregory A. Demopulos. “The assignment of a permanent, product-specific J-code for YARTEMLEA establishes a clear and consistent reimbursement pathway across payors, reducing administrative burden, supporting faster access for patients, and delivering more predictable reimbursement for providers.”

The U.S. Food and Drug Administration approved Yartemlea in December for the treatment of TA-TMA in adults and children aged two years and older. The company is now eyeing an approval for the treatment by the European Medicines Agency by mid-2026.

How Did Retail Traders React?

On Stocktwits, retail sentiment around OMER stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.

A Stocktwits user highlighted the company’s partnership with Danish drugmaker Novo Nordisk (NVO).

Omeros and Novo entered into a definitive asset purchase and license agreement in October for the candidate drug zaltenibart in clinical development for rare blood and kidney disorders. Under the deal, Omeros is eligible to receive up to $2.1 billion, including milestone payments.

Yet another Stocktwits user applauded the J-code as “actually huge” and voiced optimism for it driving commercial acceleration of Yartemlea.

OMER stock has gained about 97% over the past 12 months. 

Read More: PBM Stock On Track For Best Week In Over 2 Years On Hopes For Upcoming Executive Order To Ease Ibogaine Research

For updates and corrections, email newsroom[at]stocktwits[dot]com.